2021 IASLC World Conference on Lung Cancer

Expert Review

The year-end oncology congress season kicked off with the annual IASLC World Conference on Lung Cancer.

While it took place in virtual format from September 8-14, this proved yet again to be an important international gathering of researchers, clinicians, and professionals in the field of lung cancer and thoracic oncology.

World Lung 2021 was filled with educational and engaging sessions.

If you were unable to attend or simply need a recap, we have got you covered. This article pack, produced by our team of award-winning journalists, provides an expert review of the top trends and key issues discussed during the conference.

HIGHLIGHTS

WHAT’S IN
THE PACK?




Front-line competition lines up behind Keytruda:

Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
Tecentriq’s reduced role in adjuvant lung cancer looks likely

Tecentriq’s approvability for the adjuvant treatment of PD-L1-negative NSCLC patients is a long shot, and the drug also looks unlikely to play a role in those with stage I disease.
Treme stands up
to scrutiny:

Full data from the Poseidon study confirm the anti-CTLA-4 MAb’s activity; with three chemo combos established, however, will it be enough?
Zepzelca salvages pride from the Atlantis wreckage

Full data from the trial position the Pharmamar/Jazz small-cell lung cancer drug to remain safely on the US market.

China challenges and tremelimumab rises

This conference preview article explores key trends, including AstraZeneca’s Poseidon study, which raised tremelimumab from the dead.
Thumbnail
Thumbnail